By Colin Kellaher
ARCA biopharma shares more than doubled and hit a new 52-week high in early trading Wednesday after the clinical-stage biopharmaceutical company said it has agreed to a reverse merger with privately held biotechnology company Oruka Therapeutics.
Shares of the Westminster, Colo., company were recently changing hands at $3.63, up 112%, after touching a 52-week high of $3.82 early in the session.
ARCA said its current shareholders will own around 2.38% of the combined company, which will focus on Oruka's portfolio of biologics targeting chronic skin diseases.
The company also plans to pay a dividend of roughly $20 million to shareholders immediately prior to the deal closing, which would equal around $1.38 a share based on ARCA's 14.5 million shares outstanding as of Jan. 31.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 03, 2024 10:35 ET (14:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.